Fresenius Medical Care Corporation (FMS) Stake Cut by Jarislowsky Fraser Ltd

Jarislowsky Fraser Ltd decreased its stake in Fresenius Medical Care Corporation (NYSE:FMS) by 0.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 291,315 shares of the company’s stock after selling 1,605 shares during the period. Jarislowsky Fraser Ltd’s holdings in Fresenius Medical Care Corporation were worth $14,079,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the company. Level Four Advisory Services LLC boosted its stake in shares of Fresenius Medical Care Corporation by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock valued at $478,000 after buying an additional 58 shares during the last quarter. Intrust Bank NA boosted its position in Fresenius Medical Care Corporation by 0.8% in the first quarter. Intrust Bank NA now owns 13,219 shares of the company’s stock valued at $557,000 after buying an additional 99 shares in the last quarter. Wrapmanager Inc. boosted its position in Fresenius Medical Care Corporation by 3.5% in the first quarter. Wrapmanager Inc. now owns 7,222 shares of the company’s stock valued at $304,000 after buying an additional 244 shares in the last quarter. World Asset Management Inc boosted its position in Fresenius Medical Care Corporation by 1.0% in the first quarter. World Asset Management Inc now owns 38,273 shares of the company’s stock valued at $1,612,000 after buying an additional 369 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Fresenius Medical Care Corporation by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock valued at $149,000 after buying an additional 420 shares in the last quarter. 2.84% of the stock is currently owned by institutional investors.

Shares of Fresenius Medical Care Corporation (NYSE FMS) traded up 2.00% during mid-day trading on Friday, reaching $45.85. 235,508 shares of the company traded hands. The firm’s 50 day moving average price is $47.66 and its 200-day moving average price is $44.76. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The company has a market capitalization of $28.14 billion, a P/E ratio of 20.02 and a beta of 0.47.

Fresenius Medical Care Corporation (NYSE:FMS) last announced its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The company had revenue of $4.47 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the firm earned $0.96 earnings per share. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. Equities analysts predict that Fresenius Medical Care Corporation will post $2.33 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was reported by BNB Daily and is the property of of BNB Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/13/jarislowsky-fraser-ltd-reduces-stake-in-fresenius-medical-care-corporation-fms-updated-updated-updated.html.

Several equities analysts recently issued reports on FMS shares. Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a report on Tuesday, April 25th. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 1st. DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Monday, May 29th. Finally, BidaskClub lowered shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $48.67.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply